Clinical Trial Highlights

Somatuline sales: continuing to decline gradually Now around one third of total sales Somatuline quarterly sales growth Q1 Q2 2022 2023 2023 Q1 Q2 Q3 Q4 2022 2022 2022 2.9% 0% -0.7% -9.8% -9.8% |-13.3% -14.1% H1 2023 -12.0% sales growth North America -9.6% Solid volume-demand growth Ongoing adverse pricing Europe -21.7% Generic competition continuing to impact Somatuline autogel® lanreotide -8% -16% Rest of World +6.3% Solid underlying growth Several markets performing well, including Latin America IPSEN Innovation for patient care All growth rates are at constant exchange rates. Due to rounding, sum of percentages may not agree to totals. In this presentation, Europe is defined as the E.U., the U.K., Iceland, Liechtenstein, Norway and Switzerland. 6

View entire presentation